Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

This study is currently recruiting participants.
Verified October 2012 by Kocaeli Derince Education and Research Hospital
Sponsor:
Information provided by (Responsible Party):
Kocaeli Derince Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT01701830
First received: October 3, 2012
Last updated: October 4, 2012
Last verified: October 2012

October 3, 2012
October 4, 2012
October 2012
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01701830 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease
The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Department of Nephrology, Check-up clinic

  • Non-diabetic Chronic Kidney Disease
  • Atherosclerosis
Not Provided
  • Case Group
    Patients with chronic kidney disease of stage 3-4.
  • Control group
    30 healthy subject
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
85
May 2013
Not Provided

Inclusion Criteria:

  • between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion Criteria:

  • Chronic kidney disease of stage 5
  • The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
  • Severe heart failure
  • Stage 2 hypertension
  • Diabetes mellitus
  • Corticosteroid therapy
  • Severe hepatic disease
  • Smoking
  • Inflammatory disease
  • Acute infectious disease
  • Malignancy
Both
18 Years to 75 Years
Yes
Not Provided
Turkey
 
NCT01701830
2012/02
Not Provided
Kocaeli Derince Education and Research Hospital
Kocaeli Derince Education and Research Hospital
Not Provided
Principal Investigator: Erkan SENGUL, MD Kocaeli Derince Education and Training Hospital
Kocaeli Derince Education and Research Hospital
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP